Incyte

Incyte’s official Twitter. Ready to Solve On. See our Community Guidelines:

[Incyte @Incyte]

#News: Japan’s Ministry of Health, Labour and Welfare (MHLW) approved our treatment for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Learn more. https://t.co/ZgG1Xv0Wtc

[Incyte @Incyte]

Pablo Cagnoni reflects on the importance of the new data we shared for our mutCALR-targeted monoclonal antibody in patients with myeloproliferative neoplasms (MPNs) at the @EHA_Hematology Congress. #EHA2026 https://t.co/h6Gj6gIACM

[Incyte @Incyte]

We shared new positive data for our mutCALR-targeted monoclonal antibody in patients with myelofibrosis (MF) and essential thrombocythemia (ET) at the @EHA_Hematology Congress. Learn more about these data. #EHA2026 https://t.co/NMuVZ3l1Uh

[Incyte @Incyte]

We are proud to share Phase 3 data at the @EHA_Hematology Congress, underscoring our commitment to advancing care for patients with diffuse large B-cell lymphoma (DLBCL). Learn more. #EHA2026 https://t.co/hPHG2rkZBt

[Incyte @Incyte]

Today, the prestigious Plenary Abstracts Session at the @EHA_Hematology Congress highlighted data from the Phase 3 frontMIND trial for patients with previously untreated, high-risk diffuse large B-cell lymphoma (DLBCL). Learn more. #EHA2026 https://t.co/etJTQJhqvp

[Incyte @Incyte]

We're sharing data from our Hematology portfolio at this year's @EHA_Hematology Congress. Check out our press release for more details and stay tuned for updates. #EHA2026 https://t.co/9u5tyUj2Bo

[Incyte @Incyte]

We’re looking forward to presenting data from our Hematology portfolio at this year’s @EHA_Hematology Congress! Read our press release to learn more. #EHA2026 https://t.co/QMaP5V7Onf

[Incyte @Incyte]

Incyte announced an agreement to acquire Vega Therapeutics, a wholly owned subsidiary of @Star_biotech, strengthening our hematology portfolio and expanding our work into bleeding disorders. Read more: https://t.co/rCXWDWgXhi

[Incyte @Incyte]

Learn more from Steven Stein, M.D., Executive Vice President, Chief Medical Officer and Head of Late-stage Development, as he discusses the significance of the Phase 3 frontMIND data for patients with previously untreated diffuse large B-cell lymphoma (DLBCL), shared at this year’s @ASCO Meeting. https://t.co/VIMDQ4E3I0

[Incyte @Incyte]

Today at the American Society of Clinical Oncology® (@ASCO) Annual Meeting we shared new data from the pivotal frontMIND trial in patients with previously untreated, high-risk diffuse large B-cell lymphoma (DLBCL), simultaneously published in @TheLancet. Learn more. #ASCO26 https://t.co/0jD8ZpCLHA

[Incyte @Incyte]

Explore data from our oncology portfolio being presented at the American Society of Clinical Oncology® (@ASCO) Annual Meeting. #ASCO26 https://t.co/mMGRfds3pk

[Incyte @Incyte]

Incyte to present the latest data from our oncology portfolio at the upcoming American Society of Clinical Oncology® (@ASCO) Annual Meeting. Learn more. #ASCO26 https://t.co/NxjYhAZpB6

[Incyte @Incyte]

Our purpose remains constant: delivering meaningful medicines for patients. Incyte continues to advance with real momentum and a clear plan for long-term growth and innovation. Learn more. https://t.co/cH91bU3foy

[Incyte @Incyte]

Incyte and @genesismolai are expanding our collaboration designed to accelerate the discovery of potential new medicines. Learn more. https://t.co/OBAcoMxU8n

[Incyte @Incyte]

Excited for our partnership with Edison Scientific. Read more here: https://t.co/NF0LJbVeAB

[Sam Rodriques @SGRodriques]

We live in a golden age of biology. So why are people still dying from disease?

Because discovery and development move slower than they should.

Today, we’re partnering with Incyte to change that.

Kosmos is now the first agent that can compress months of drug development into weeks, from the earliest stages of scientific discovery through to FDA approval. @Incyte will be the first company to deploy it across their pipeline.

Work that used to take a team of scientists months now happens in weeks.

Patients can't wait, and neither can we.

[Incyte @Incyte]

We’re proud to share that we have been named to LinkedIn’s inaugural Philadelphia Top Companies list. This recognition reflects the people behind our work. A team united by purpose, committed to advancing science and focused on making a difference for patients. #SolveOn https://t.co/RAp14Aceyu

[Incyte @Incyte]

We are excited to announce a strategic collaboration with @EdisonSci to employ the Kosmos AI platform across Incyte's discovery and development lifecycle. Read more. https://t.co/t7TdtJNIXG

[Incyte @Incyte]

Incyte will be presenting data from our Hematology and Oncology pipeline at the 2026 @EHA_Hematology Congress in Stockholm. Stay tuned for updates and read more about our data. #EHA2026 https://t.co/VLcucLYAo7

[Incyte @Incyte]

At this year’s #EADVSymposium, we shared data in patients with moderate atopic dermatitis (AD). Learn more about these data. https://t.co/KlUHZIWnDe

[Incyte @Incyte]

At Incyte, we’re committed to advancing research and solutions to help address patient needs and preferences. We are proud to announce the @US_FDA approval of a new, once-daily formulation of our therapy for MPNs and GVHD. Learn more. https://t.co/uroZ6uJXoJ